Abstract: A method and device for inserting a tongue in an insertion groove in a panel. The method includes displacing a first tongue to an end position of a tongue queue, which comprises tongues under compression, in a tongue queue device, compressing the first tongue, displacing the tongues in the tongue queue by compression forces from the tongues under compression, displacing a second tongue, which is at a front position of the tongue queue, to an inserting device, displacing the second tongue into an insertion groove in a panel by said inserting device.

Abstract: A method and device for managing and separating a tongue from a tongue blank, including cutting a first edge of a tongue from the tongue blank by rotating a tool which includes a protruding part, and displacing the tongue by the protruding part to a tongue queue. The method and device may include a second tool for cutting a second edge of the tongue from the tongue blank.

Abstract: A method and device for inserting a tongue in an insertion groove in a panel by a device, wherein the method includes: displacing a tongue guiding device in a first direction by displacing a puncher in the first direction, and displacing a tongue between a first part and a second part of the tongue guiding device and into an insertion groove in panel by further displacing the puncher.

Abstract: The present invention relates to a syringe having a barrel, a plunger arranged to travel within said barrel and a plunger rod for driving the plunger in a bidirectional manner. The plunger rod is provided with a head at a distal end thereof and a plurality of protruding finger grip enhancing means axially spaced along a length of the plunger rod.

Abstract: A device and a method for attaching a resealable opening device (2) on a package (1), the device comprising an attachment unit (100) having at least one carrier member (101) being movable between a pick-up position and an attachment position, in which latter the carrier member (101) is arranged for attachment of the opening device on the package by means of relative movement between the carrier member and the package. The device further comprises an abutment (113) and a knife arrangement (112), wherein the at least one carrier member, in said pick-up position, is arranged for relative movement towards the abutment for engagement with a web (12) of interconnected opening devices arranged therebetween and for pick-up of one opening device; and wherein the knife arrangement is arranged to cooperate with the carrier member and the abutment or cutting out the opening device during the engagement of the carrier member with the web.

Abstract: The present invention relates to pharmaceutical compositions comprising anakinra as an active compound in the absence of sodium citrate. The said pharmaceutical compositions are useful for the treatment of IL-1 mediated disorders and for decreasing nociceptive pain during such treatment.

Abstract: The present invention relates to pharmaceutical compositions comprising anakinra as an active compound in the absence of sodium citrate. The said pharmaceutical compositions are useful for the treatment of IL-1 mediated disorders and for decreasing nociceptive pain during such treatment.

Abstract: Gel compositions are provided that can be utilized as carriers for beneficial agents when injected into a subject and which can provide sustained release of the beneficial agent over time. In particular, gel compositions containing an agent that renders the composition thixotropic to facilitate injection of the gel into a subject with minimal discomfort to the subject are described.

Abstract: The present invention relates to pharmaceutical compositions comprising anakinra as an active compound in the absence of sodium citrate. The said pharmaceutical compositions are useful for the treatment of IL-1 mediated disorders and for decreasing nociceptive pain during such treatment.

Abstract: A device for the serial ejection of at least two fluid components comprises a spacer (19) providing at least two states, i) a first state allowing a front piston (7) to be displaced forwards by action on a rear piston (17) while a fluid volume is retained in a rear chamber (5) and ii) a second state allowing the rear chamber to volumetrically shrink while fluid is transferred past (or through) the front piston thereby enabling the use of a liquid, initially provided in only the rear chamber, for the dual purposes of mixing and rinsing.

Abstract: A device for the serial ejection of at least two fluid components comprises a spacer (19) providing at least two states, i) a first state allowing a front piston (7) to be displaced forwards by action on a rear piston (17) while a fluid volume is retained in a rear chamber (5) and ii) a second state allowing the rear chamber to volumetrically shrink while fluid is transferred past (or through) the front piston thereby enabling the use of a liquid, initially provided in only the rear chamber, for the dual purposes of mixing and rinsing.

Abstract: Gel compositions are provided that can be utilized as carriers for beneficial agents when injected into a subject and which can provide sustained release of the beneficial agent over time. In particular, gel compositions containing an agent that renders the composition thixotropic to facilitate injection of the gel into a subject with minimal discomfort to the subject are described.

Abstract: The invention relates to solutions containing IGF-1 or any functional analogue thereof in which pH is 5.5 to 6.5, preferably 5.7 to 6.2. The amount of phosphate as buffer substance should be in a concentration of less than 50 mmol/L Preferably the formulation is an aqueous solution of IGF-1 and phosphate as buffer substance in a concentration of 5 to 50 mmole or more preferably 5-20 mmol/L, e.g. 10 mmol/L. The solution should be isotonic. The solution gives a reduced pain upon subcutaneous injection. The invention also relates to a process for preparation of the formulation by mixing IGF-1 or any functional analogue thereof with a buffer substance giving pH 5.5 to 6.5 and an isotonic agent. It also relates to a method for treatment of a patient in need of IGF-1 or any functional analogue thereof by administering the claimed formulation.